12:00 AM
 | 
Oct 11, 2010
 |  BioCentury  |  Product Development

CAP-ping Inflammation

Israel's Atox aiming at inflammation in community acquired pneumonia

While most compounds in development for community-acquired pneumonia are antibiotics designed to disrupt bacterial replication, Atox Bio Inc. hopes it can improve survival by addressing the role of inflammation in the disease. The biotech started its first Phase I study last month to assess the safety and pharmacokinetics of lead molecule AB103.

"In severe CAP, patients die not just because of the bacteria, but also due to the severe inflammatory response triggered by toxins and other bacterial components that cause necrosis in the lungs," CEO Dan Teleman told BioCentury.

Upon infection, antigen-presenting cells (APCs) engage with T cells to activate a cytokine cascade, including release of the inflammatory factor tumor necrosis factor (TNF) alpha.

Rather than knocking out TNF alpha or other inflammatory factors in the cascade, which can leave patients immunocompromised and therefore more vulnerable to infection, Atox is seeking to modify the interaction between APCs and T cells to temper the inflammatory response.

Specifically, the company...

Read the full 787 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >